Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes

被引：0
|
作者：
Elza Muscelli
Brenno Astiarraga
Elisabetta Barsotti
Andrea Mari
Freimut Schliess
Leszek Nosek
Tim Heise
Uli C. Broedl
Hans-Juergen Woerle
Ele Ferrannini
机构：
[1] University of Pisa,Department of Clinical and Experimental Medicine
[2] C.N.R. Institute of Neuroscience,undefined
[3] Profil,undefined
[4] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined
[5] CNR Institute of Clinical Physiology,undefined
来源：
Diabetologia | 2016年 / 59卷
关键词：
Empagliflozin; Endogenous glucose production; Glycosuria; Metformin; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：700 / 708
页数：8
相关论文
共 50 条
  • [31] THE EFFICACY OF COMBITATION OF EMPAGLIFLOZIN AND METFORMIN IN PATIENTS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS
    Zhuravlyova, Larysa
    Filonenko, Maryna
    Rogachova, Tetyana
    Sokolnikova, Nelly
    JOURNAL OF HYPERTENSION, 2023, 41 : E194 - E194
  • [32] Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy
    Mannucci, Edoardo
    Ghetti, Gianni
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2022, 23 (01) : 85 - 95
  • [33] Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea
    Shin, Yujin
    Moon, Ji Hye
    Chin, Ho Jun
    Ferrannini, Ele
    Lim, Soo
    ENDOCRINOLOGY AND METABOLISM, 2020, 35 (02) : 329 - 338
  • [34] Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
    Mojca Lunder
    Miodrag Janić
    Miha Japelj
    Andrej Juretič
    Andrej Janež
    Mišo Šabovič
    Cardiovascular Diabetology, 17
  • [35] Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
    Lunder, Mojca
    Janic, Miodrag
    Japelj, Miha
    Juretic, Andrej
    Janez, Andrej
    Sabovic, Miso
    CARDIOVASCULAR DIABETOLOGY, 2018, 17
  • [36] The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus
    Erdem, Gokhan
    Dogru, Teoman
    Tasci, Ilker
    Bozoglu, Ergun
    Muhsiroglu, Ozlem
    Tapan, Serkan
    Ercin, Cemal Nuri
    Sonmez, Alper
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 82 (02) : 214 - 218
  • [37] The efficacy of pioglitazone compared to metformin in drug naive patients with type 2 diabetes
    Schernthaner, G
    Edwards, G
    Lee, C
    Tan, M
    Herz, M
    DIABETES, 2003, 52 : A455 - A455
  • [38] Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naive Chinese patients: Analysis of results from the CONSENT trial
    Ji, Linong
    Liu, Jing
    Yang, Jing
    Li, Yufeng
    Liang, Li
    Zhu, Dalong
    Li, Quanmin
    Ma, Tianrong
    Xu, Haiyan
    Yang, Yanlan
    Zeng, Jiaoe
    Feng, Bo
    Qu, Shen
    Li, Yiming
    Ma, Lizhen
    Lin, Shanshan
    Wang, Jianping
    Li, Wei
    Song, Weihong
    Li, Xiaoxing
    Luo, Yong
    Xi, Shugang
    Lin, Mei
    Liu, Yu
    Liang, Zerong
    DIABETES OBESITY & METABOLISM, 2018, 20 (04): : 1006 - 1013
  • [39] Metabolic modelling of the human gut microbiome in type 2 diabetes patients in response to metformin treatment
    Bouchra Ezzamouri
    Dorines Rosario
    Gholamreza Bidkhori
    Sunjae Lee
    Mathias Uhlen
    Saeed Shoaie
    npj Systems Biology and Applications, 9
  • [40] Metformin and the Risk of Chronic Urticaria in Patients with Type 2 Diabetes
    Yen, Fu-Shun
    Hsu, Chih-Cheng
    Hu, Kai-Chieh
    Hung, Yu-Tung
    Hsu, Chung Y.
    Wei, James Cheng-Chung
    Hwu, Chii-Min
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (17)
12345